Compare Invesco Ltd. (IVZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs TG Therapeutics Inc — how do they compare? Invesco Ltd. trades at $29.52 (market cap $13.28B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and TG Therapeutics Inc for 16 Days on average.
| IVZ | TGTX | |
|---|---|---|
Market Cap | $13.28B | $8.16B |
Volume | 3,698,033 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $33.31 | $59.06 |
52-Week Low | $22.44 | $26.94 |
Typical Hold Time | 77 Days | 16 Days |
Enterprise Value | $23.45B | $8.37B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.
The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
